Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996435 · ClinicalTrials.gov registry record · Phase 4
Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation
A Phase 4 study, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- Phase 4
- Development phase
- 139
- Enrollment target
NCT02996435 is a Phase 4 study that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 139 participants.
The verdict
NCT02996435, a Phase 4 study, has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 139 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the effectiveness of an intervention with a mobile adherence platform, compared to physician- or nurse-guided standard of care, to improve medication adherence to rivaroxaban in participants who have recently initiated treatment with rivaroxaban for stroke prevention in atrial fibrillation based on an assessment of the proportion of days covered (PDC) of rivaroxaban treatment.
Interventions
- OTHER No Intervention
- BEHAVIORAL Mobile Application Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2016-12-21 |
| Est. Completion | 2018-03-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02996435
The ClinicalTrials.gov registry entry for NCT02996435 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which No Intervention is the first listed.
NCT02996435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02996435 about?
NCT02996435 is a clinical study titled "Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation". The primary purpose of this study is to evaluate the effectiveness of an intervention with a mobile adherence platform, compared to physician- or nurse-guided standard of care, to improve medication adherence to rivaroxaban in participants who have recently initiated treatment with rivaroxaban for s...
What is the current status of trial NCT02996435?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 139 participants. The study started on 2016-12-21. Estimated completion is 2018-03-22.
What interventions are being tested in trial NCT02996435?
The interventions under investigation include: No Intervention (OTHER), Mobile Application Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT02996435?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.